|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:academic_programs
|
Ms. Anna Red
|
|
gptkbp:acquisition
|
gptkb:Crux_Biomedical
gptkb:C._R._Bard
gptkb:Care_Fusion
gptkb:Acelity
gptkb:Bard_Medical
gptkb:Care_Fusion_Corporation
Cypress Diagnostics
Graham-Field Healthcare
|
|
gptkbp:advertising
|
gptkb:Mr._Richard_Roe
gptkb:Ms._Emily_White
Mr. Alan Brown
|
|
gptkbp:awards
|
gptkb:S&_P_500
gptkb:Fortune_500
gptkb:Diversity_Inc_Top_50
Best Places to Work
Corporate Responsibility Magazine's 100 Best Corporate Citizens
|
|
gptkbp:ceo
|
gptkb:Tom_Polen
|
|
gptkbp:competitors
|
gptkb:Abbott_Laboratories
gptkb:Roche_Diagnostics
gptkb:Thermo_Fisher_Scientific
gptkb:Siemens_Healthineers
gptkb:Medtronic
|
|
gptkbp:conducts_research_on
|
gptkb:Dr._John_Smith
|
|
gptkbp:employees
|
approximately 70,000
|
|
gptkbp:founded
|
1897
|
|
gptkbp:founder
|
gptkb:William_Dickinson
gptkb:Maxwell_Becton
Fairleigh S. Dickinson
|
|
gptkbp:global_presence
|
over 50 countries
|
|
gptkbp:has_authority_over
|
gptkb:Mr._David_Black
|
|
gptkbp:head
|
gptkb:Ms._Laura_Blue
gptkb:Tom_Polen
|
|
gptkbp:head_of_state
|
gptkb:Ms._Jane_Doe
gptkb:Ms._Sarah_Green
|
|
gptkbp:headcount
|
70,000
|
|
gptkbp:headquarters
|
gptkb:Franklin_Lakes,_New_Jersey
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Becton, Dickinson and Company
|
|
gptkbp:industry
|
Medical technology
|
|
gptkbp:innovation
|
Molecular Diagnostics
Surgical Instruments
Automated Blood Culture Systems
Smart Syringe Technology
|
|
gptkbp:location
|
gptkb:Franklin_Lakes,_New_Jersey
|
|
gptkbp:market_cap
|
$70 billion (2022)
|
|
gptkbp:partnership
|
gptkb:Global_Fund
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:Centers_for_Disease_Control_and_Prevention
gptkb:World_Health_Organization
gptkb:American_Red_Cross
gptkb:Gavi,_the_Vaccine_Alliance
gptkb:National_Institutes_of_Health
PATH
|
|
gptkbp:philanthropy
|
BD Foundation
|
|
gptkbp:products
|
gptkb:Needles
Syringes
Diagnostic systems
Blood collection systems
Diagnostic instruments
|
|
gptkbp:research_and_development
|
$1.5 billion (2022)
|
|
gptkbp:revenue
|
$17.1 billion (2022)
|
|
gptkbp:stock_symbol
|
BDX
|
|
gptkbp:subsidiary
|
gptkb:BD_Medical
gptkb:BD_Interventional
gptkb:BD_Biosciences
gptkb:BD_Diagnostics
|
|
gptkbp:supply_chain
|
Mr. Mark Yellow
|
|
gptkbp:sustainability_initiatives
|
gptkb:BD_2025_Sustainability_Goals
Social responsibility
Environmental stewardship
Governance practices
|
|
gptkbp:traded_on
|
gptkb:New_York_Stock_Exchange
|
|
gptkbp:type
|
gptkb:Public
|
|
gptkbp:website
|
www.bd.com
|
|
gptkbp:bfsParent
|
gptkb:Bard
gptkb:urban_park
|
|
gptkbp:bfsLayer
|
4
|